Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection

The distribution of serotypes of group B streptococci (GBS) isolated from 67 infants with early-onset sepsis are described. Case-infants were assembled from 13 hospitals across the United States from 15 July 1995 to 5 February 1997 through prospective active surveillance. The distribution of GBS ser...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infectious diseases Jg. 177; H. 3; S. 790
Hauptverfasser: Lin, F Y, Clemens, J D, Azimi, P H, Regan, J A, Weisman, L E, Philips, 3rd, J B, Rhoads, G G, Clark, P, Brenner, R A, Ferrieri, P
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.03.1998
Schlagworte:
Bacterial Capsules - classification
Bacterial Capsules - immunology
Humans
Infant, Newborn
Prospective Studies
Sepsis - microbiology
Serotyping
Streptococcal Infections - microbiology
Streptococcus agalactiae - classification
Streptococcus agalactiae - immunology
ISSN:0022-1899
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The distribution of serotypes of group B streptococci (GBS) isolated from 67 infants with early-onset sepsis are described. Case-infants were assembled from 13 hospitals across the United States from 15 July 1995 to 5 February 1997 through prospective active surveillance. The distribution of GBS serotypes was Ia, 40%; Ib, 9%; II, 6%; III, 27%; V, 15%; and nontypeable, 3%. Type V occurred more frequently in the northeast region (New York and New Jersey) than in other regions (29% vs. 9%, P = .06). Conversely, type III occurred significantly less frequently in the northeast region than other regions (10% vs. 35%, P = .04). GBS types Ia, III, and V accounted for 82% of the isolates. This report supports previous observations about the emergence of GBS type V, but our data caution that conclusions about serotype distributions based on one geographic location or on a small number of patients may not be generally applicable. Continued monitoring seems necessary for the design of a GBS vaccine.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-1899
DOI:10.1086/517810